Roche, a leader in research-focused healthcare, announced that new Esbriet (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, September 26-30, 2015.

Roche is supporting nine different abstracts on IPF data. In addition, Roche is sponsoring two medical symposia to explore treatment strategies in IPF and to highlight the importance of personalised medicines for people with severe asthma.

“Roche is committed to bringing transformative medicines to people with severe respiratory diseases,” said Sandra Horning, M.D., Roche’s chief medical officer and head of global product development.

“Our focus at this meeting will be on new data with Esbriet in idiopathic pulmonary fibrosis and the emerging science on the importance of personalised medicines for severe asthma.”

Roche research being presented as part of the ERS 2015 scientific programme and ongoing respiratory research will be showcased during the Roche media event from September 29 at the Amsterdam RAI Exhibition and Convention Centre ERS Press Conference Room. Leading experts will speak about new IPF management guidelines and Esbriet clinical data and the need for personalised medicines for severe uncontrolled asthma patients.

Roche will also hold two educational symposia on IPF and type 2 asthma. The first, entitled “Strategies to improve treatment outcomes in IPF,” will be held on September 27. The second, entitled “Putting the spotlight on Type 2 biomarkers in severe asthma,” will take place on September 28.